Health Trials

Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease

ConditionsChronic Kidney Disease Stage 4Chronic Kidney Disease Stage 3BChronic Kidney Disease Stage 5Diabetes MellitusFluorescein AngiographyAcute Kidney Injury
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSaint-Joseph University

About this trial

Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.

Eligibility criteria

Qualifiers

>18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR<45 mL/min/1.73 m2)

Disqualifiers

Patients who do not give their consent

Patients who are allergic to fluorescein

Patients who are on dialysis

Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention

Trial design

Treatments tested in this trial

  • Fluorescein angiography

Treatment groups

35 Participants
are divided into 1 treatment group

Sponsors and collaborators

Saint-Joseph University

Lead sponsor

Source ClinicalTrials.gov